Relates to providing information to patients and the public on hospital rule-based exclusions; requires the commissioner of health to collect from each hospital a list of its hospital rule-based exclusions and publish such information on the department's website.
This bill (A 565) prohibits the establishment of new for-profit hospices and bans capacity increases for existing for-profit hospices. It applies to all approvals after the law takes effect, directly affecting for-profit hospice providers and their expansion plans. The law requires new hospice facilities to operate as non-profits and prevents existing for-profit hospices from growing their services. This represents a concrete change in healthcare regulation, restricting for-profit models in hospice care.
Requires public notice and public engagement when a general hospital seeks to close entirely or a unit that provides maternity, mental health or substance use care.
Relates to including outpatient care provided by creative arts therapists in certain insurance policies covering care for other mental health services.
S 123 bans the sale of infant walkers by all sellers (manufacturers, distributors, retailers, and secondhand dealers) in New York State. It also restricts the use of infant walkers in child care facilities, requiring medical necessity approval from a professional for any exception. Child care facilities must receive plain-language notice about the ban and follow rules set by the Office of Children and Family Services. The law allows the attorney general to enforce the ban through injunctions and impose civil penalties for violations.
S 3294 updates New York's medical cannabis program by extending the validity of patient and caregiver registry cards from one to two years, streamlining certification processes for doctors, and clarifying possession limits. It requires practitioners to complete training before issuing certifications, allows special certifications for patients with progressive conditions, and permits patients to possess up to a 60-day supply of cannabis (aligning with existing penal law). The bill directly affects certified patients, designated caregivers, and healthcare providers by modernizing documentation, reducing administrative burdens, and updating expiration rules. It repeals the outdated Controlled Substances Therapeutic Research Act, consolidating the program under revised cannabis law provisions. This law took effect after being signed by the governor in November 2025.
Creates a department of health education and outreach program on reproductive health services for consumers, patients, educators, and health care providers related to reproductive health services available in New York state including, but not limited to: access to family planning services such as contraceptives and pregnancy testing, testing and treatment for sexually transmitted infections; makes related provisions.
This bill (A 7321) would require New York health insurers to cover speech therapy for stuttering when recommended by a physician. It applies to all medical, major medical, and similar insurance plans, eliminating limits on the number of therapy sessions or visits. Coverage must be provided by licensed professionals and clarifies that school-based therapy (like IEPs) does not affect medical coverage for therapy outside educational settings. The bill was vetoed by the governor in October 2025 and did not become law.
This bill repeals a requirement in New York's public health law that previously mandated healthcare providers to report patients' drug use to authorities. It directly affects healthcare practitioners who no longer must report such information under this provision. The bill removes this specific reporting obligation with no new mechanisms or provisions added. As a procedural repeal, it solely eliminates the existing legal requirement without creating new policies. The bill was enacted after passing both legislative chambers and receiving the Governor's signature in October 2025.
Clarifies that certain provisions related to statewide opioid settlement agreements shall cover settlements and releases related to any entities involved in the prescription drug marketing, supply and payment chain that may have contributed to the opioid epidemic through illegal conduct.